A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Clinical trial NCT07680764 · RECRUITING

Trial details

NCT number: NCT07680764
Sponsor: Bristol-Myers Squibb
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Locally Advanced Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung Cancer (NSCLC)

Start date: 2026-08-15
Primary completion: 2028-09-15
Enrollment: 160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.